|
||||||
|
|
Sharing the Corporate Crown JewelsReprint 44312; Spring 2003, Vol. 44, No. 3, pp. 89–93
The full text of this article is available free to all site visitors, compliments of IBM, as part of our ongoing Business Insight series. Jointly produced by MIT Sloan Management Review and The Wall Street Journal, Business Insight offers fresh thinking on crucial management issues supplemented by the deep knowledge of related, classic SMR articles, of which this is one. Read the Business Insight article to which it relates and other SMR classics on the topic, all free full text.
Intellectual property assets now account for 50% to 70% of the market value of all public companies, and corporate America is intensifying efforts to maximize the return on those assets. That explains why a small but growing number of Fortune 500 enterprises are moving away from a strict reliance on the "exclusivity value" of their patents and other intellectual property — that is, their power to exclude or hinder competitors — and are instead seeking to tap the often enormous financial and strategic value of their core technology assets by licensing them to other companies, including competitors. The practitioners of this strategic licensing, as it is called, are betting that any loss of market exclusivity that may result from making available their "crown jewel" technologies will be more than offset by the financial and strategic benefits gained. For this article, the author interviewed some of the pioneer practitioners of this emerging approach and got them to explain the nature and degree of the benefits their companies are now reaping. Although patent rights should always remain an important weapon in a company's competitive arsenal, strategic-licensing initiatives are encouraging managers to rethink what it means to create and sustain competitive advantage in business. is a specialist in intellectual property strategy and coauthor of "Rembrandts in the Attic: Unlocking the Hidden Value of Patents" (Harvard Business School Press, 2000). He can be reached at dkline@well.com.
Academic pricing and volume discount information
|
|